Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

Rubinstein-Taybi Syndrome Clinical Trial

— RUBIVAL  

Official title:

Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01619644
• Other study ID #: CHUBX 2011/20
• Status: Completed
• Phase: Phase 2
• First received: June 12, 2012
• Last updated: March 17, 2015
• Start date: April 2012
• Est. completion date: September 2014

Study information

• Verified date: March 2015
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

An exploratory phase 2 therapeutic trial in children from 6 to 21, RTS carriers, randomized to be treated either with sodium valproate with the usual pediatric dosage (30 mg/kg/j), or by placebo for one year.

The investigator would like to include children because they could best profit from it due to their neuronal plasticity as CBP and EP300 take effect through neuronal and synaptic plasticity.

The therapeutic effect of sodium valproate in RTS patients will be assessed thanks to a clinical approach (learning and memory neuropsychological evaluation, fine motor skills assessment by pointing), to a biological approach (histone acetylation functional tests), and to imaging (morphological and functional MRI).

Description:

Such a multidisciplinary approach has never been presented for this syndrome; it should enable us identifying specific cognitive and motor deficits and their association thanks to imaging markers. Assessing the various aspects of motor skills, i.e. primary (movements, standing at ease position, immobility) and complex motor skills (actions and behaviours, motor aspects of feelings and language expressions) is an integral part of the clinical examination in psychiatrics.

The main interest of a functional capacity analysis is to be used as an index allowing the assessment of the nervous system's global capacities and the study of the connections between cognitive functions and motor skills Main objective: Evaluate long term memory with subtest "point location" - CMS and "image recognition" RBMT A patient is said to be responder if after one year his or her test result increase for one point at least one of the two tests : a increase of one point to "point location" or "image recognition".

Double-blind phase 2 clinical trial, designed as a one-step Fleming design but with a control group. Rubival is a two-parallel group randomized trial:

• a placebo group of 20 patients

• a group of 40 patients taking sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Years to 21 Years

Eligibility

Inclusion Criteria:

• Children over 6 and under 21

• RTS confirmed by a genetic study with a CBP gene or EP300 gene mutation

• Sufficient cognitive capacities for neuropsychological evaluation

• Free and informed consent of the parents or guardians

• Children affiliated to or benefiting of the French social welfare system

Exclusion Criteria:

• Contraindication to sodium valproate

• Women of reproductive age without effective contraception means

• Case history of sodium valproate treatment

• Monotherapy treatment for epilepsy with Lamictal with a dosage superior to 5 mg/kg/j

• Family history of severe hepatitis including drug

• Acute or chronic hepatitis

• Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Craniofacial Abnormalities
• Hand Deformities, Congenital
• Rubinstein-Taybi Syndrome
• Syndrome

Intervention

Drug:
• sodium valproate
sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
• Placebo
Placebo with an oral dosage of 30 mg/kg/jour

Locations

Country	Name	City	State
France	University Hospital Bordeaux, France	Bordeaux

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Bordeaux	Fondation Syndrome de Rubinstein-Taybi

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Memory tests (assessing memory learning)	The main outcome measure was to evaluate long term memory with two subtests : point location, subtest of CMS (children memory scale). The score ranges from 0 to 6; image recognition, subtest of RBMT (Rivermead Behavioural Memory Test). The score range from 0 to 10. One point for each image recognized A patient is said to be responder if after one year of treatment , his or her test result increase for one point at least one of the two tests	1 year	No
Secondary	Special brain imaging profile and motor skills (posturology and motor coordination in a visio-manual pointing task)	For motor skills, the profile was based on 3 tasks : posturology, motor coordination in a visuo-manual pointing task and in mobile interception task..; For brain imaging, a variety of outcome measures will be used for example, brain volume, anisotropy fraction, diffusion coefficient for structural magnetic imaging and the signal intensity for functional Magnetic Resonance Imaging	1 year	No
Secondary	Cognitive and developmental profile	Based on the results of several battery test and evaluation scale, VABS II (Vineland Adaptative Behaviour Scale II), Leiter R, EVIP, ECOSSE, NEPSY : fluency verbal sutest, CMS : 2 subtests, RBMT : 1 subtest	1 year	No
Secondary	Histone acetylation profile		1 year	No
Secondary	Global acetylation level		1 year	No
Secondary	Acetylation level of selected gene		1 year	No
Secondary	Measurement of selected gene expression		1 year	No